Edwards Lifesciences (NYSE:EW) Target Lowered by Morgan Stanley to $83.00

0
26
Businessman with magnifying glass search of investing and stock market. Gain and profits with candlestick charts. Stock Market Analysis. Finance data concept.

Edwards Lifesciences stock has undergone multiple analysts rating changes in the recent past.  Edwards Lifesciences stock Target Lowered by   Morgan Stanley on 6/29/2020. In a note to investors, the firm issued a new target price of $83.00. The analysts previously had $83.33 target price. Morgan Stanley’s price target would indicate a potential upside of 23.64% from the stock’s previous close.

Shares of Edwards Lifesciences traded up $0.37 on Monday, reaching $67.50. 428543 shares of the stock traded hands, compared to its average volume of 3291761. Shares of were trading at $67.50 on Monday. The firm’s 50 day moving average is $$71.87 and its 200 day moving average is $73.76.Edwards Lifesciences  has a 12 month low of $66.73 and a 12 month high of $225.10. While on yearly highs and lows, Edwards Lifesciences today has traded high as $67.89 and has touched $66.73 on the downward trend.

Edwards Lifesciences Earnings and What to expect: 

Edwards Lifesciences last released its earnings results on April 23rd, 2020. The medical research company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.03 billion. Its revenue for the quarter was up 13.7% on a year-over-year basis. Edwards Lifesciences has generated $1.86 earnings per share over the last year and currently has a price-to-earnings ratio of 38.5. Edwards Lifesciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, July 28th, 2020 based off prior year’s report dates.

Earnings for Edwards Lifesciences are expected to grow by 30.91% in the coming year, from $1.65 to $2.16 per share. The P/E ratio of Edwards Lifesciences is 38.51, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.03. The P/E ratio of Edwards Lifesciences is 38.51, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.14. Edwards Lifesciences has a PEG Ratio of 2.53. PEG Ratios above 1 indicate that a company could be overvalued. Edwards Lifesciences has a P/B Ratio of 10.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Latest Insiders Trading and Volume : 

  • Insider Ownership Percentage: 1.48%
  • On 6/22/2020 CFO Scott B Ullem Sell 26,700 at average share price of $69.51 which equates to $1,855,917.00 in money value.
  • On 6/16/2020 VP Catherine M Szyman Sell 3,348 at average price of  $70.67 with total value of : Not Data Available
  • On 6/15/2020 CEO Michael A Mussallem Sell 68,550 at average price of  $68.28 with total value of : $4,680,594.00
  • See More Analyst Rating at: RATING

Other Analyst’s rating for Edwards Lifesciences

  • 6/2/2020 – Edwards Lifesciences had its price target lowered by analysts at Credit Suisse Group AG to $88.00. They now have an “outperform” rating on the stock.
  • 6/1/2020 – Edwards Lifesciences had its price target lowered by analysts at Morgan Stanley from $83.33 to $83.00. They now have an “overweight” rating on the stock.
  • 4/28/2020 – Edwards Lifesciences was downgraded by analysts at Wells Fargo & Co from an “overweight” rating to an “equal weight” rating. They now have a $76.67 price target on the stock, down previously from $83.33.
  • 4/27/2020 – Edwards Lifesciences had its “underweight” rating re-affirmed by analysts at Barclays PLC. They now have a $51.67 price target on the stock, down previously from $55.00.
  • See More Analyst Rating at: RATING

Other rating updates by Morgan Stanley: 

  • 6/29/2020 – PG&E had its price target lowered by analysts at Morgan Stanley from $13.00 to $11.00. They now have an “equal weight” rating on the stock.
  • 6/29/2020 – Spotify had its price target raised by analysts at Morgan Stanley from $190.00 to $275.00. They now have an “overweight” rating on the stock.
  • 6/29/2020 – ZoomInfo Technologies is now covered by analysts at Morgan Stanley. They set an “equal weight” rating and a $50.00 price target on the stock.
  • 6/26/2020 – RIGHTMOVE PLC/ADR had its “equal weight” rating re-affirmed by analysts at Morgan Stanley.
  • See More Analyst Rating at: RATING

Edwards Lifesciences (NYSE:EW) Moving Average Technical Analysis

5 day Moving Average is $$68.19 And 5 day price change is -$2.30 (-3.29%)  with average volume for 5 day average is 2,549,655. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $70.81 and 20 day price change is -$6.76 (-9.10%) and average 20 day moving volume is 3,222,494. 50 day moving average is $71.87  and 50 day price change is -$8.63 ( -11.33%)  and with average volume for 50 days is : 3,227,872. 200 day moving average is $73.76  and 200 day price change is -$5.97 (-8.13%)  and with average volume for 200 days is : 4,048,577.

See More Analyst Rating at: RATING